Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Preferred Stock Liabilities came in at $310.6 million in Q1 2018, up 159.32% quarter-over-quarter from $119.8 million in Q4 2017.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Preferred Stock Liabilities for 2 consecutive years, with $310.6 million the latest figure, recorded in Q1 2018.
- For the quarter ending Q1 2018, Preferred Stock Liabilities changed N/A year-over-year to $310.6 million; the trailing twelve-month figure through Mar 2018 stood at $310.6 million (changed N/A YoY), and the FY2017 full-year result was $119.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities improved to $310.6 million in Q1 2018 per KNSA's latest filing, from $119.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $310.6 million in Q1 2018 and bottomed at $119.8 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Kiniksa Pharmaceuticals International | 6.12 Bn | 5.60 Bn | 220.03 Mn | - |